Previous close | 2.2800 |
Open | 2.5600 |
Bid | 2.4000 x 0 |
Ask | 2.7000 x 0 |
Day's range | 2.5200 - 2.5600 |
52-week range | 2.3200 - 2.5600 |
Volume | |
Avg. volume | 0 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholdsPureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTechTransaction provides further non-dilutive capital for PureTech’s growing and rapidly advancing Wholly Owned Pipeline, with five clinical-stage candidates expected by the end of 2023 NEW
BOSTON & NEW YORK, March 23, 2023--PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million
BOSTON, March 01, 2023--PureTech to Present at the Barclays Global Healthcare Conference